Cardio-green butyl acetate targets ergosterol to kill Candidaalbicans Authors: Piyush Baindara, Suresh K. Mondal, Dinata Roy, Sourav Chakraborty, Dheeraj Kumar Sarkar, Santi M. Mandal, Gourisankar Ghosh Published: 2026 ABSTRACT SummaryThe rising incidence of invasive Candida infections highlights the urgent need for distinct antifungal agents with improved safety and efficacy. Although several antifungal drugs are clinically available, their associated toxicity and the increasing emergence of drug-resistant Candida species often result in poor therapeutic outcomes. In this study, we report the antifungal potential of cardio-green butyl acetate (CaGA), a previously unknown synthesized compound, and investigate its activity and mechanism of action. CaGA exhibited strong fungicidal activity against Candida albicans, significantly reducing planktonic cell viability and biofilm biomass. Membrane disruption was demonstrated by protein leakage assays, Nile red and live/dead staining, and scanning electron microscopy. Isothermal titration calorimetry (ITC) confirmed direct interaction between CaGA and ergosterol, the major sterol component of the C. albicans membrane. Coarse-grained membrane simulations further revealed preferential interaction with ergosterol-rich domains and pore-like structure formation. Together, these findings identify CaGA as a promising next-generation antifungal candidate with a distinct membrane-targeting mechanism, offering therapeutic potential against drug-resistant Candida infections. Introduction Fungal infections caused by Candida species, particularly C. albicans, represent a significant and growing global health burden. C. albicans is responsible for a wide spectrum of diseases ranging from superficial mucosal infections to life-threatening systemic candidiasis, especially in immunocompromised individuals.1 The increasing incidence of drug-resistant Candida strains, biofilm-associated persistence, and the limited efficacy of existing antifungal drugs have intensified the need for the development of previously uncharacterized, more effective, and safer antifungal agents.2 Candida often forms co-infections with bacterial strains, leading to more severe and complicated infections. This synergistic interaction can worsen patient outcomes and complicate treatment strategies.3,4 Among the currently available antifungals, amphotericin B (AmB) remains a gold-standard treatment due to its broad-spectrum activity and fungicidal nature.5,6 AmB exhibits anti-Candida activity by binding to ergosterol, a key component of fungal cell membranes, and forming transmembrane pores that lead to ion leakage and cell death.7 Notably, clinical uses of AmB are limited due to serious dose-limiting toxicities, particularly nephrotoxicity and infusion-related side effects.8,9 Overall, the emergence of rapid drug resistance, along with the lack of available drugs with safety profiles, highlights the urgent need for alternative compounds to combat pathogenic C. albicans. Cardio-green (C43H47N2NaO6S2) (CaG), also known as indocyanine green, is an FDA (Food and Drug Administration)-approved tricarbocyanine dye widely utilized as a near-infrared fluorescent probe in clinical diagnostics and imaging. It has been extensively applied in cardiac output monitoring, hepatic function assessment, ophthalmic angiography, and intraoperative imaging due to its favorable safety profile, strong plasma protein binding, and deep tissue penetration capabilities.10,11 Interestingly, CaG is reported to bind specifically to lipoprotein and lipids, including sterols such as cholesterol.12 In the present study, we have synthesized a modified derivative of CaG, cardio-green butyl acetate (CaGA), to enhance its stability, lipophilicity, membrane binding, and biological activity while investigating the anti-Candida properties in comparison to AmB. We employed an integrative approach combining in vitro assays and coarse-grain molecular dynamics (MD) simulations using asymmetric ergosterol-rich bilayers mimicking the C. albicans membrane to characterize CaGA’s mechanism of action. By presenting detailed experimental and simulation-based evidence, this study suggested that CaGA might be a foundation for next-generation antifungal classes with the potential to overcome the limitations of current therapies. Results The final product (Figure 1) was purified and confirmed using 1H nuclear magnetic resonance (1H NMR) spectroscopy, which validated the successful modification of CaG into its butyl acetate-functionalized derivative CaGA. 1HNMR: 1.62–1.69, 6H (m), 1.84–1.86, 3H (m), 2.07, 6H (S), 2.08, 4H (S), 2.46–2.56, 8H (m), 2.75, 2H (S), 2.89, 2H (S), 3.29, 16H (S), 3.51–3.54, 4H (t), 4.02, 2H (S), 5.02–5.06, 1H (m), 5.26–5.42, 1H (m), 6.02–6.06, 2H (m), 6.42–6.49, 2H (m), 7.74–7.86, 5H (m), 7.93–8.21,5H (m) (Figure S1).Figure 1Synthesis and structural confirmation of CaGA(A) Two-step synthetic route showing conversion of CaG into its butyl acetate-functionalized derivative (CaGA). Step 1: formation of bromo-butyl acetate intermediate; Step 2: substitution reaction yielding CaGA. Synthesis and structural confirmation of CaGA (A) Two-step synthetic route showing conversion of CaG into its butyl acetate-functionalized derivative (CaGA). Step 1: formation of bromo-butyl acetate intermediate; Step 2: substitution reaction yielding CaGA. CaGA efficiently kills C. albicans The antifungal efficacy of CaGA against C. albicans was examined by treating planktonic cells, followed by plating on agar media and colony counting to determine the minimum inhibitory concentration. Treatment with CaGA led to a significant, dose-dependent reduction in colony-forming units (CFUs), indicating its inhibitory effect on proliferation increases with concentration. Quantitative analysis revealed a significant reduction of more than 85% and 99% of viable colonies at 4 μg/mL and 8 μg/mL of CaGA, respectively, when compared to untreated controls (Figure 2A). These results demonstrate that CaGA efficiently kills C. albicans and establishes its potential as an antifungal agent, comparable to the frontline antifungal drug, AmB.Figure 2Antifungal activity of CaGA against C. albicans(A) CFU assay reveals a dose-dependent inhibition of C. albicans, where complete inhibition was observed at 16 μg/mL of CaGA.(B) Intracellular leakage of C. albicans with 4 μg/mL of CaGA for 0, 5, 10, 20, 30, and 60 min. AmB was used as a positive control.(C) SEM micrograph of untreated and treated C. albicans with 4 μg/mL of CaGA.(D) Nile red staining assay of C. albicans at 4 μg/mL of CaGA. Untreated (PBS) C. albicans was used as a negative control. All the experiments were performed three times independently in triplicate, while statistical significance was considered at the level of p < 0.05. Error bars represent standard deviation (SD). Antifungal activity of CaGA against C. albicans (A) CFU assay reveals a dose-dependent inhibition of C. albicans, where complete inhibition was observed at 16 μg/mL of CaGA. (B) Intracellular leakage of C. albicans with 4 μg/mL of CaGA for 0, 5, 10, 20, 30, and 60 min. AmB was used as a positive control. (C) SEM micrograph of untreated and treated C. albicans with 4 μg/mL of CaGA. (D) Nile red staining assay of C. albicans at 4 μg/mL of CaGA. Untreated (PBS) C. albicans was used as a negative control. All the experiments were performed three times independently in triplicate, while statistical significance was considered at the level of p < 0.05. Error bars represent standard deviation (SD). CaGA targets membrane-associated killing mechanisms To further confirm the anti-Candida activity of CaGA and to assess the effect on C. albicans membrane integrity, a protein leakage assay was performed by measuring UV absorbance at 260 nm. Treatment of C. albicans with CaGA at 4 μg/mL for 5, 10, 20, 30, and 60 min time points exhibited a significant increase in extracellular protein content when compared to untreated controls (Figure 2B). The elevated absorbance at 260 nm indicates leakage of intracellular proteins or protein-nucleic acid complexes into the extracellular environment, suggesting compromised cell membrane integrity. This leakage correlated with a significant reduction in cell viability, confirming that CaGA exerts its anti-Candida effect by disrupting the cell membrane, leading to cell death. Further, scanning electron microscopy (SEM) was performed to examine the morphological impact of the CaGA on C. albicans cells. Notably, C. albicans cells treated with CaGA at 4 μg/mL exhibit significant signs of structural damage in comparison to the control cells. SEM images revealed surface deformities such as wrinkling, membrane blebbing, cell shrinkage, and irregular cell shapes, along with disrupted cell membranes, indicative of compromised cellular integrity (Figure 2C). Additionally, Nile red staining was performed on treated C. albicans cells to check if membrane sterols or intracellular lipids are altered or disrupted upon CaGA treatment and contribute to the killing mechanism. Interestingly, the increased Nile red fluorescence observed in C. albicans cells treated with 4 μg/mL of CaGA suggests the disruption of membrane lipid domains, likely due to altered ergosterol content or membrane fluidity, consistent with a membrane-targeted antifungal mechanism (Figure 2D). Additionally, fluorescence microscopy revealed altered membrane morphology and patchy distribution of lipid domains in treated cells compared to untreated controls. These observations support the hypothesis that CaGA might interact with ergosterol in the C. albicans membrane, potentially perturbing membrane integrity and contributing to its antifungal activity. Together, these findings demonstrate that CaGA exerts potent antifungal effects against C. albicans by disrupting membrane integrity, inducing morphological damage, and thus reducing viability. CaGA efficiently eradicates C. albicans biofilm The ability of CaGA to eradicate C. albicans biofilm was evaluated using the crystal violet (CV) assay. Treatment with CaGA at a 32 μg/mL of CaGA concentration resulted in a significant reduction in biofilm biomass of C. albicans compared to untreated controls (Figure 3A). Interestingly, the biofilm removal efficacy of CaGA was comparable to that of AmB, which was used as a positive control. Quantitative analysis showed that C. albicans biofilm biomass was reduced by approximately 25% and 85%, respectively, at 16 μg/mL and 32 μg/mL concentration of CaGA. At the same time, AmB exhibits about 50% and 90% reduction in C. albicans biofilm mass at 8 μg/mL and 16 μg/mL of concentration, respectively (Figure 3A). These results confirmed the potent antibiofilm activity of CaGA against C. albicans biofilm. Further, the viability of CaGA-treated C. albicans biofilms was evaluated using the live/dead BacLight staining assay. Untreated control biofilms exhibited predominantly green fluorescence (SYTO9), indicating intact cell membranes and high viability (Figure 3B). In contrast, C. albicans biofilms treated with CaGA at a 4 μg/mL concentration for 60 min revealed a significant increase in red fluorescence (PI), indicative of compromised cell membrane and cell death (Figure 3B). Overall, these results demonstrate that CaGA exerts potent antifungal effects on C. albicans biofilms, compromising membrane integrity and thus significantly reducing cell viability.Figure 3Biofilm eradication potential of CaGA(A) Crystal violet assay shows efficient eradication of C. albicans biofilms in comparison to the AmB. C. albicans treated with PBS 1% Triton X-100 were used as negative and positive controls, respectively.(B) Fluorescence microscopic image of live/dead biofilm eradication assay of untreated biofilms (upper panel), and treated biofilms (lower panel) for 1 h at 4 μg/mL of CaGA (i) sytox green, (ii) propidium iodide, and (iii) merged. Error bars represent SD, while statistical significance is considered at the level of p < 0.05. All the experiments were performed three times independently in triplicate. Biofilm eradication potential of CaGA (A) Crystal violet assay shows efficient eradication of C. albicans biofilms in comparison to the AmB. C. albicans treated with PBS 1% Triton X-100 were used as negative and positive controls, respectively. (B) Fluorescence microscopic image of live/dead biofilm eradication assay of untreated biofilms (upper panel), and treated biofilms (lower panel) for 1 h at 4 μg/mL of CaGA (i) sytox green, (ii) propidium iodide, and (iii) merged. Error bars represent SD, while statistical significance is considered at the level of p < 0.05. All the experiments were performed three times independently in triplicate. CaGA binds to ergosterol, leading to C. albicans cell death The interaction between C. albicans cell membrane sterol, ergosterol, and CaGA was primarily investigated using UV absorbance spectroscopy. Upon incubation of different concentrations of ergosterol with CaGA at a 100 μg/mL concentration, significant changes in the UV absorbance spectrum were observed compared to ergosterol alone. Specifically, a notable shift and/or decrease in the characteristic ergosterol absorbance peak at 282 nm indicated binding or complex formation between CaGA and ergosterol (Figure 4A). These spectral changes provide strong evidence of a direct interaction of CaGA with ergosterol, which may underlie its mechanism of disrupting C. albicans cell membranes and thus exerting antifungal effects.Figure 4Biophysical characterization of CaGA-ergosterol interaction(A) UV-visible absorption spectra of CaGA in the presence of increasing ergosterol concentrations showing a decrease and red shift of the ergosterol peak at 282 nm, consistent with complex formation.(B) ITC profile shows an exothermic binding event (ΔH = −3.02 × 103 cal/mol·K, K = 3.2 × 104 M−1). The thermodynamic parameters indicate a spontaneous, enthalpy-driven interaction involving hydrophobic and hydrogen-bonding forces between CaGA and ergosterol. Biophysical characterization of CaGA-ergosterol interaction (A) UV-visible absorption spectra of CaGA in the presence of increasing ergosterol concentrations showing a decrease and red shift of the ergosterol peak at 282 nm, consistent with complex formation. (B) ITC profile shows an exothermic binding event (ΔH = −3.02 × 103 cal/mol·K, K = 3.2 × 104 M−1). The thermodynamic parameters indicate a spontaneous, enthalpy-driven interaction involving hydrophobic and hydrogen-bonding forces between CaGA and ergosterol. Isothermal titration calorimetry (ITC) was performed to further confirm the interaction between CaGA and ergosterol. Key parameters for interaction, including Gibbs free energy (ΔG), enthalpy change (ΔH), entropy change (TΔS), binding affinity (K), and stoichiometry (n), were quantitatively assessed using ITC in the present study. The binding isotherms and thermograms demonstrated a strong interaction between the CaGA and ergosterol, with an estimated binding constant (K) of 3.20 × 104 M−1. Notably, the binding event was characterized as an exothermic reaction, and the enthalpy of binding was −3.02 × 103 cal/mol·K (Figure 4B). The significant heat changes recorded throughout the titration reflect the distinct thermodynamic signature of the interaction, revealing strong, specific non-covalent binding between the CaGA and ergosterol. Collectively, these findings confirm the high binding affinity and reveal the underlying thermodynamic forces governing the interaction, highlighting the potential of CaGA as a potent binder to ergosterol, possibly contributing to the antifungal mechanism of CaGA against C. albicans. Translocation of CaGA across the asymmetric C. albicans membrane To investigate the membrane translocation behavior and thermodynamic feasibility of CaGA, steered molecular dynamics (SMD) simulations were conducted while AmB was used as a comparative control. To generate a force versus distance curve profile, the center of mass of the CaGA and AmB was pulled along the z axis, spanning from −4 nm to +4 nm, which defined the reaction coordinate (RC) across the fungal bilayer (Figure 5). A constant pulling velocity of 0.1 nm/ns and a harmonic force constant of 100 kJ mol−1nm−2 were applied to simulate transport from the outer membrane surface to the inner leaflet region. The force-distance profiles derived from SMD trajectories revealed distinct energy barriers for both CaGA and AmB (Figure 5). Notably, CaGA exhibited its highest force peak during egress from the membrane interior, suggesting a strong retention within the bilayer and a potentially deeper membrane interaction. Specifically, a peak force of 133 kJ mol−1 nm−1 was required to pull CaGA out of the membrane, indicating significant bilayer engagement (Videos S1 and S2). In contrast, AmB demonstrated its maximum force barrier of 138 kJ mol−1 nm−1 during entry, suggesting it faces a higher energy requirement upon initial membrane insertion (Figure 6). These findings underscore the distinct membrane-interaction dynamics of CaGA, highlighting its potential for stable bilayer insertion and membrane-disruptive antifungal activity against C. albicans.Figure 5Comparative MD simulation of AmB and CaGA interactions with ergosterol-rich membranes(A) Snapshot shows AmB (magenta) inserting deeply into the ergosterol-rich bilayer (ergosterol in orange), forming a transmembrane channel-like arrangement.(B) Snapshot shows CaGA (cyan) remaining near the membrane surface while engaging ergosterol via hydrogen bonding and hydrophobic contacts, indicating a surface-associated, non-pore-forming mode of action.(C) RC profiles from steered MD simulations illustrate the relative depth of membrane penetration over time for AmB and CaGA.(D) Corresponding force profiles show that AmB requires a higher pulling force to cross the bilayer, reflecting stronger lipid disruption, whereas CaGA maintains lower energy perturbations consistent with membrane thinning rather than pore formation.(E) Time evolution of hydrogen bonds, demonstrating transient but frequent interactions for CaGA compared with AmB.Figure 6Representative membranes showing CaGA and AmB embedded in the C. albicans bilayer(A) Molecular system of AmB is inserted above the outer membrane (OT) region.(B) Molecular system of CaGA near the OT region. The ergosterols are shown in orange spheres, and other lipids are indicated as lines. The phosphate head is shown in red spheres, and the water molecules are represented as transparent surfaces in gray color. For SMD, the compounds were steered from the outer membrane (OT) to the inner membrane (IN) region. The starting (C) and final (D) conformations of CaGA while translocating the cell membrane of C. albicans. Comparative MD simulation of AmB and CaGA interactions with ergosterol-rich membranes (A) Snapshot shows AmB (magenta) inserting deeply into the ergosterol-rich bilayer (ergosterol in orange), forming a transmembrane channel-like arrangement. (B) Snapshot shows CaGA (cyan) remaining near the membrane surface while engaging ergosterol via hydrogen bonding and hydrophobic contacts, indicating a surface-associated, non-pore-forming mode of action. (C) RC profiles from steered MD simulations illustrate the relative depth of membrane penetration over time for AmB and CaGA. (D) Corresponding force profiles show that AmB requires a higher pulling force to cross the bilayer, reflecting stronger lipid disruption, whereas CaGA maintains lower energy perturbations consistent with membrane thinning rather than pore formation. (E) Time evolution of hydrogen bonds, demonstrating transient but frequent interactions for CaGA compared with AmB. Representative membranes showing CaGA and AmB embedded in the C. albicans bilayer (A) Molecular system of AmB is inserted above the outer membrane (OT) region. (B) Molecular system of CaGA near the OT region. The ergosterols are shown in orange spheres, and other lipids are indicated as lines. The phosphate head is shown in red spheres, and the water molecules are represented as transparent surfaces in gray color. For SMD, the compounds were steered from the outer membrane (OT) to the inner membrane (IN) region. The starting (C) and final (D) conformations of CaGA while translocating the cell membrane of C. albicans. Video S1. Coarse-grained membrane simulation of AmB binding ergosterol and translocating across the C. albicans membrane Video S1. Coarse-grained membrane simulation of AmB binding ergosterol and translocating across the C. albicans membrane Video S2. Coarse-grained membrane simulation of CaGA binding ergosterol and translocating across the C. albicans membrane Video S2. Coarse-grained membrane simulation of CaGA binding ergosterol and translocating across the C. albicans membrane CaGA kills C. albicans by a distinct interaction with ergosterol To elucidate the molecular basis of antifungal action, all-atom MD simulations were conducted to investigate the interaction of CaGA with ergosterol-containing asymmetric membranes representative of C. albicans. Interestingly, CaGA is primarily localized at the membrane interface, engaging in extensive hydrogen bonding and hydrophobic interactions with ergosterol’s polar head groups and sterol rings. CaGA disrupted the lateral organization of ergosterol and surrounding phospholipids, leading to membrane destabilization and altered fluidity. This disruption potentially compromises membrane integrity, thus exhibiting killing. On the other hand, AmB exhibited strong affinity for ergosterol-rich membrane regions, inserting deeply into the lipid bilayer. This interaction facilitated the formation of stable transmembrane channels, characterized by the aggregation of AmB molecules surrounding ergosterol clusters, consistent with the classical pore-forming mechanism. Moreover, both compounds exhibited the highest degree of ergosterol engagement during the 20–35 ns window of the SMD trajectory, suggesting that this time frame corresponds to a critical interaction phase as the molecules traverse the hydrophobic core of the membrane (Figure 7). Notably, CaGA formed hydrogen bonds with ergosterol, primarily mediated via its oxygen atoms, indicating specific and directional interactions stabilizing its position within the lipid bilayer (Figure 5). Overall, the membrane simulations revealed that CaGA binding induces significant local membrane thinning and increased lipid disorder via ergosterol, which is also possibly involved in the promotion of ion permeability and cell leakage. Together, these simulation results provide atomistic insights into how CaGA differentially targets C. albicans through ergosterol binding, advancing understanding of its antifungal mechanism of action and informing rational design of emerging therapeutics.Figure 7Initial and final conformations of AmB and CaGA in C. albicans during SMD(A) The starting and (B) final conformations of AmB while translocating the C. albicans membrane. (C) The starting and (D) final conformations of CaGA while translocating the C. albicans membrane. Initial and final conformations of AmB and CaGA in C. albicans during SMD (A) The starting and (B) final conformations of AmB while translocating the C. albicans membrane. (C) The starting and (D) final conformations of CaGA while translocating the C. albicans membrane. Discussion The growing prevalence of drug-resistant Candida infections continues to challenge current antifungal therapy. AmB, a polyene macrolide, remains a benchmark treatment because of its broad-spectrum activity and potent fungicidal action. However, its severe nephrotoxicity and infusion-related adverse effects limit clinical use, emphasizing the need for safer antifungal agents with comparable efficacy.5,6 In this context, we developed and characterized CaGA, a previously unknown synthesized derivative of indocyanine green, and evaluated its antifungal mechanism using both experimental assays and MD simulations. Our findings establish that CaGA exerts strong antifungal activity against C. albicans by directly compromising the fungal membrane. CFU assays and live/dead staining revealed a clear dose-dependent reduction in viability (Figures 2A and 2B), while biofilm assays showed that CaGA significantly reduced biofilm biomass, performing comparably to AmB (Figure 3). This dual effect on planktonic and biofilm cells highlights CaGA’s potential therapeutic advantage, since biofilms are typically more resistant to conventional antifungals.13 Mechanistically, multiple lines of evidence indicate that CaGA’s antifungal activity is membrane-centric and ergosterol-dependent. The rise in UV absorbance at 260 nm following CaGA treatment suggests leakage of intracellular components due to membrane rupture (Figure 2B). SEM further confirmed severe morphological distortions, including wrinkling, shrinkage, and cell deformation (Figure 2C). Importantly, Nile red staining demonstrated increased lipid-domain fluorescence and patchy distribution patterns in treated cells (Figure 2D), consistent with altered ergosterol-rich microdomains and membrane fluidity changes. Together, these observations support a model in which CaGA interacts directly with fungal sterols rather than acting as a nonspecific detergent. Direct ergosterol-binding assays further substantiate this conclusion. Next, UV-visible spectroscopy revealed spectral shifts upon ergosterol addition, and ITC demonstrated a strong, exothermic binding reaction (ΔH = −3.02 × 103 cal/mol·K) with a moderate binding affinity (K = 3.2 × 104 M−1) (Figures 4A and 4B). This thermodynamic signature suggests that CaGA forms a stable non-covalent complex with ergosterol, driven by hydrophobic and hydrogen-bonding interactions. Additionally, MD simulations provided deeper mechanistic insight into how these interactions influence membrane structure. CaGA localized near the membrane surface, engaging in multiple hydrogen bonds with ergosterol’s hydroxyl groups and disrupting local lipid packing. Unlike AmB, which penetrates the bilayer and forms transmembrane ion channels, CaGA remained surface-associated and induced localized thinning of the membrane. This non-pore-forming but membrane-destabilizing mechanism likely promotes leakage and ion imbalance without creating permanent pores. The lower energetic barrier observed in steered MD simulations implies that CaGA associates with ergosterol-rich regions with minimal perturbation of surrounding lipids, potentially leading to reduced off-target toxicity compared with AmB.14,15 Taken together, these findings define CaGA as a membrane-selective antifungal agent that kills C. albicans by destabilizing ergosterol-dependent lipid organization. This is mechanistically distinct from AmB and other polyenes, which form rigid transmembrane channels that can also disrupt mammalian cholesterol membranes.16 CaGA’s preferential interaction with ergosterol over cholesterol could therefore provide a broader therapeutic window. The strong antibiofilm activity observed further aligns with its membrane-targeted mechanism. Biofilm formation in Candida depends on intact plasma membrane signaling, adhesion proteins, and lipid-domain organization. Disruption of ergosterol-rich microdomains likely impairs these functions, weakening biofilm cohesion and viability. The combined activity against both planktonic and biofilm cells suggests that CaGA can overcome one of the primary challenges in antifungal therapy, biofilm-associated tolerance to antifungal agents.17 Although these results position CaGA as a promising antifungal candidate, further investigation is warranted. Future work should evaluate its selectivity index, in vivo safety, and pharmacokinetics to confirm therapeutic potential. Structural analogs of CaGA could also be explored to fine-tune ergosterol affinity and optimize membrane selectivity. In summary, CaGA acts as a distinct, ergosterol-targeting antifungal that disrupts fungal membranes through a non-pore-forming, membrane-destabilizing mechanism. This dual action-potent fungicidal activity and biofilm disruption, combined with likely lower cytotoxicity underscores its potential as a next-generation antifungal agent capable of addressing the limitations of existing therapies. Overall, this study identifies CaGA as a distinct antifungal molecule that targets fungal membranes through specific interaction with ergosterol. Its distinct mechanism and membrane-selective action highlight potential advantages in safety and efficacy compared with existing agents. Overall, CaGA shows strong promise as a next-generation therapeutic candidate for C. albicans, including biofilm-associated and drug-resistant infections. Limitations of the current study This study provides strong experimental and computational evidence that CaGA acts as a distinct ergosterol-targeting antifungal. Still, a few areas warrant further investigation. The work focused on a single C. albicans strain to establish proof of mechanism; testing across clinical and non-albicans species will help define the broader activity range. Next, ergosterol binding was confirmed by multiple complementary methods; we did not measure total ergosterol content before and after treatment, as this would have been largely redundant. Further, cytotoxicity toward mammalian cells was not evaluated here, but CaGA’s preference for ergosterol over cholesterol suggests a favorable safety profile to be verified in future in vitro studies. Likewise, while live/dead and CFU assays showed consistent results, formal statistical correlation was not performed since both already supported the same trend. Finally, in vivo studies will be needed to confirm safety, pharmacokinetics, and resistance potential under physiological conditions. Overall, these limitations define clear next steps for advancing CaGA from a validated in vitro candidate to a promising antifungal lead. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Santi M. Mandal (smmandal@ucsd.edu). Materials availability This study did not generate new or unique reagents. Data and code availability •Data: None.•Code: None.•All other items: None. •Data: None. Data: None. •Code: None. Code: None. •All other items: None. All other items: None.